Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8306527 | 0.84 | ALDH1A1 (0.47) | KDM4EALDH1A1MAPTHSD17B10TLR4 | |
| SCHEMBL8229856 | 0.81 | CD44 (0.35) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8306529 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1MAPTHSD17B10TLR4 | |
| SCHEMBL8269433 | 0.78 | ALDH1A1 (0.41) | KDM4EALDH1A1MAPTHSD17B10TLR4 | |
| SCHEMBL8291075 | 0.73 | KDM4E (0.38) | KDM4EALDH1A1MAPTHSD17B10TLR4 | |
| SCHEMBL8292367 | 0.73 | NNMT (0.37) | KDM4EALDH1A1MAPTHSD17B10TLR4 | |
| SCHEMBL14490504 | 0.73 | L3MBTL1 (0.42) | KDM4EALDH1A1MAPTHSD17B10TLR4 | |
| SCHEMBL2264173 | 0.70 | GAA (0.39) | CD44TLR4 | |
| SCHEMBL12665748 | 0.69 | ALDH1A1 (0.53) | KDM4EALDH1A1MAPTHSD17B10TLR4 | |
| SCHEMBL377405 | 0.69 | MAPT (0.53) | KDM4EALDH1A1MAPTHSD17B10TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901139-B2 | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901139-B2 | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8404845-B2 | 2,3-substituted azaindole derivatives for treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404845-B2 | 2,3-substituted azaindole derivatives for treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| WO-2009032125-A1 | 2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| WO-2006041831-A2 | CYCLIC Β-AMINO ACID DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2004082687-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | IDO1, IDO2, ZC3HAV1 | CD44 2175/4885KDM4E 2071/4885ALDH1A1 2482/4885 |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | CD44 4609/4885KDM4E 2254/4885ALDH1A1 3204/4885 |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | CD44 2996/4885KDM4E 1597/4885ALDH1A1 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.